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We included patients who received rituximab either as single-agent, or in combination with steroids or other immunosuppressants. A minimum of 1 clinic or laboratory follow-up visit every 8 weeks was required to be included in the study, as well as a minimum follow-up of 1 year. As a general rule, complete blood counts were performed at every follow-up visit. Patients with immune-mediated hematologic disorders related to a malignant hematologic condition were excluded.
In all included patients, date of initial and last rituximab infusion, rituximab dosing (milligrams or milligrams per meter square), number of rituximab doses, and pre-treatment absolute neutrophil count (ANC) were obtained. ANCs were reviewed from first rituximab infusion to at least 12 months from last rituximab infusion. Neutropenia was defined as an ANC of less or equal to 1.5 x 10 3 neutrophils/µL and was classified as mild (1 to 1.5), moderate (0.6 to <1), and severe (≤0.5). For those patients who developed neutropenia, the 'time to neutropenia' was calculated from first rituximab infusion to an ANC of ≤ 1.5 x 10 3 neutrophils/µL. ANC nadir and the dates when mild, moderate, and severe neutropenia occurred was recorded. The 'time to recovery from neutropenia' was determined from the time of first neutropenia occurrence (ANC≤1.5) to an ANC greater than 1.5 x 10 3 neutrophils/µL. The main study patient outcome was the 1-year probability of developing neutropenia from first rituximab infusion. Episodes of febrile neutropenia, hospitalization, infection, and use of granulocyte-colony stimulating factor (GCSF) were also analyzed. Clinical features were summarized using descriptive statistics. The 'time to neutropenia' from first rituximab infusion and the 'time to recovery from This article is protected by copyright. All rights reserved.
neutropenia' from first neutropenia occurrence were estimated using Kaplan-Meier estimators. Log-rank Tests was applied to compare between groups.
A total of 197 patients were included in the evaluation and had diagnoses of ITP n=94, TTP n=34, AIHA n=34, ACFD n=22, and APS n=13. Clinical features, treatment characteristics, and outcomes are summarized in Table 1 . The median age at diagnosis was 51 years with a female predominance (58%, n=114). The median ANC prior to rituximab initiation was 5.6 x 10 3 neutrophils/µL and the median time from diagnosis to rituximab initiation was 2.2 years. The rituximab dosing strategies used were rituximab at 375 mg/m 2 (83%, n=163) with a median of 4 doses administered, 1,000 mg (12%, n=24) with a median of 2 doses administered, and 100 mg (5%, n=10) with a median of 4 doses administered. Fourteen patients (7%) received rituximab combined with other immunosuppressive agent, the other 183 patients received either rituximab alone (n=144, 73%), or in combination with steroids (n=39, 20%).
With a median follow-up time of 1.07 years, 18% of the patients treated with rituximab for a non-malignant immune-mediated hematologic disorder developed neutropenia (mild 11%, n=21; moderate 3%, n=6, severe 4%, n=8) (Supplemental figure 1) . The probability of neutropenia at 1 year after initial rituximab infusion was 16% (11%-23%) in the rituximab alone or with steroids group versus 38% (18%-68%) in the rituximab with other immunosuppressant group (p<0.01). The median ANC nadir on those who developed neutropenia was 1.2 x 10 3 cells/µL. Of those who developed neutropenia, the median time to development of any degree of neutropenia was 4.4 months (range 1.7-12.6 months) from initial rituximab infusion (4.2 months in the rituximab alone or with steroids group and 2 months in the rituximab with other immunosuppressant group; p=0.04). Development of neutropenia was not different by gender (p=1.0), age (<60 vs. ≥60 years, p=0.07), type of hematologic disease (p=0.08), or rituximab dosing strategy (p=0.85). By contrast, rituximab given for 4 doses or more (neutropenia: n=29/142, versus ≤ 3 doses n=6/55, p=0.04) and combination therapy of rituximab with another immunosuppressive drug versus rituximab alone or with steroids (neutropenia: n=8/14, versus n=27/183, respectively, p<0.01) were significantly associated with a higher rate of neutropenia. Likewise, while numerous retrospective studies on the use of rituximab in non-malignant hematologic disorders exist 6 , they are restricted to only few hematologic conditions (i.e. ITP, and TTP) with minimal to no data regarding the prevalence and time course of neutropenia in other immune-mediated hematologic disorders. To the best of our knowledge, our retrospective study is the first study that reports on the incidence, degree and time-course of development of neutropenia in patients treated for different non-malignant immune-mediated hematologic disorders.
Our analysis demonstrates an 18% rate of neutropenia at 1-year in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic disorders which is in line with results found in patients treated with rituximab for malignant hematologic conditions. [1] [2] [3] In this study, most neutropenia cases were mild, with only 4% developing clinically significant neutropenia (ANC<0.5). Additionally, in our study rituximab given for 4 or more doses, and combination of rituximab with other immunosuppressant, as opposed to rituximab as single-agent or in combination with corticosteroids, represented a significant risk factor for the development of neutropenia, especially severe neutropenia with longer time to ANC recovery. This article is protected by copyright. All rights reserved.
In regards to infectious complications secondary to rituximab-associated neutropenia, pooling data from the major retrospective studies reveals an infection rate of around 16%; however, most infections were mild, and resolved promptly even in patients with febrile neutropenia. 1 Re-challenge with rituximab after neutropenia may result in recurrent episodes, but the implications and risks are uncertain at the present time. Likewise, whether GCSF is beneficial once neutropenia appears is unclear, but it is probably not needed. 1, 2 In our study, and acknowledging the limitations from conducting a single-center retrospective study, it is not possible for us to tell whether the use of an immunosuppressant different than corticosteroids could have been the sole cause of the observed neutropenia or if the combination of rituximab with an immunosuppressant caused a synergistically toxic effect; in any case the rate of hospitalizations, febrile neutropenia, infections and the use of GCSF did not increase, even in severe neutropenia cases.
In conclusion, development of neutropenia in patients treated with rituximab for non-malignant immunemediated hematologic disorders is an expected but relatively benign side effect. Neutropenia is more frequent if rituximab is given with other immunosuppressant other than corticosteroids, and when the number of doses of rituximab given are higher.
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